The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response

Kazuyuki Shimizu; Yoshikazu Kamiya; Junji Itoh; Jun Okada; Merrell Lim; Satoru Sugiyama

doi:10.1002/ccr3.1304

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response

Clin Case Rep. 2017 Nov 28;6(1):96-102. doi: 10.1002/ccr3.1304. eCollection 2018 Jan.

Authors

Kazuyuki Shimizu¹, Yoshikazu Kamiya¹, Junji Itoh², Jun Okada³, Merrell Lim⁴, Satoru Sugiyama⁵

Affiliations

¹ Higashi Nagoya National Hospital Nagoya Japan.
² Nagoya City Midori General Hospital Nagoya Japan.
³ Medical Biological Laboratories Nagoya Japan.
⁴ The Binding Site Group Ltd Birmingham UK.
⁵ The Institute of Applied Biochemistry Kani Japan.

Abstract

Heavy/light chain (HLC) assay will enable us to evaluate the changes in the concentrations of iHLC and uHLC separately and to better identify whether the change observed is clonal or reactive. It would therefore aid in decision making for earlier implementation or discontinuation of treatment for patients with intact immunoglobulin multiple myeloma (MM).

Keywords: Deep response; disease monitoring; involved/uninvolved HLC ratio; multiple myeloma; serum heavy/light chain (HLC) assay.

Publication types

Case Reports